[go: up one dir, main page]

FR10C0003I2 - PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS - Google Patents

PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS

Info

Publication number
FR10C0003I2
FR10C0003I2 FR10C0003C FR10C0003C FR10C0003I2 FR 10C0003 I2 FR10C0003 I2 FR 10C0003I2 FR 10C0003 C FR10C0003 C FR 10C0003C FR 10C0003 C FR10C0003 C FR 10C0003C FR 10C0003 I2 FR10C0003 I2 FR 10C0003I2
Authority
FR
France
Prior art keywords
indolinone
pyrrole
inhibitors
protein kinase
substituted protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0003C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of FR10C0003I1 publication Critical patent/FR10C0003I1/en
Application granted granted Critical
Publication of FR10C0003I2 publication Critical patent/FR10C0003I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
FR10C0003C 2000-02-15 2010-01-15 PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS Active FR10C0003I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18271000P 2000-02-15 2000-02-15
US21642200P 2000-07-06 2000-07-06
US24353200P 2000-10-27 2000-10-27
PCT/US2001/004813 WO2001060814A2 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (2)

Publication Number Publication Date
FR10C0003I1 FR10C0003I1 (en) 2010-03-05
FR10C0003I2 true FR10C0003I2 (en) 2012-06-22

Family

ID=27391578

Family Applications (2)

Application Number Title Priority Date Filing Date
FR08C0002C Active FR08C0002I2 (en) 2000-02-15 2008-01-15 PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS
FR10C0003C Active FR10C0003I2 (en) 2000-02-15 2010-01-15 PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR08C0002C Active FR08C0002I2 (en) 2000-02-15 2008-01-15 PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS

Country Status (42)

Country Link
US (4) US6573293B2 (en)
EP (1) EP1255752B1 (en)
JP (1) JP3663382B2 (en)
KR (1) KR100713960B1 (en)
CN (1) CN1329390C (en)
AR (1) AR034118A1 (en)
AT (1) ATE369359T1 (en)
AU (2) AU2001239770B2 (en)
BE (1) BE2010C009I2 (en)
BG (1) BG65764B1 (en)
BR (2) BRPI0108394B8 (en)
CA (1) CA2399358C (en)
CO (1) CO5280092A1 (en)
CR (2) CR20120007A (en)
CY (3) CY1108032T1 (en)
CZ (1) CZ303705B6 (en)
DE (3) DE122008000002I1 (en)
DK (1) DK1255752T3 (en)
EA (1) EA005996B1 (en)
ES (1) ES2290117T3 (en)
FR (2) FR08C0002I2 (en)
HR (1) HRP20020751B1 (en)
HU (1) HU228979B1 (en)
IL (1) IL151127A0 (en)
IS (1) IS2491B (en)
LT (1) LTC1255752I2 (en)
LU (2) LU91407I2 (en)
ME (1) ME00415B (en)
MX (1) MXPA02008021A (en)
MY (1) MY130363A (en)
NL (2) NL300332I2 (en)
NO (4) NO325532B1 (en)
NZ (1) NZ520640A (en)
PE (1) PE20011083A1 (en)
PL (1) PL211834B1 (en)
PT (1) PT1255752E (en)
RS (1) RS50444B (en)
SI (1) SI1255752T1 (en)
SK (1) SK287142B6 (en)
TW (1) TWI306860B (en)
UA (1) UA73976C2 (en)
WO (1) WO2001060814A2 (en)

Families Citing this family (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
DE60045474D1 (en) 1999-01-13 2011-02-17 Univ New York State Res Found NEW METHOD FOR CREATING PROTEIN KINASE INHIBITORS
DE122008000002I1 (en) * 2000-02-15 2008-04-17 Sugen Inc PYRROL SUBSTITUTED INDOLIN-2-ON PROTEIN KINASE INHIBITORS
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2001270260A1 (en) * 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
US6677368B2 (en) * 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
JP2004529110A (en) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
JP2004536097A (en) * 2001-06-29 2004-12-02 アブ サイエンス Uses of tyrosine kinase inhibitors to treat autoimmune diseases
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
BR0211612A (en) 2001-08-15 2004-08-24 Upjohn Co Crystals including a n- [2- (diethylamino) ethyl] -5 - [(5-fluoro-2-oxo-3h-indol-3-ylide) methyl] -2,4-dimethyl-1h-malic acid salt pyrrol-3-carboxamide, processes for their preparation and compositions
BR0212435A (en) * 2001-09-10 2004-08-17 Sugen Inc 3- (4,5,6,7-Tetrahydroindol-2-ylmethylidene) -2-indolinone derivatives as kinase inhibitors
JP2005508953A (en) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド 3- [4- (Substituted heterocyclyl) -pyrrol-2-ylmethylidene] -2-indolinone derivatives as kinase inhibitors
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
AU2002366245A1 (en) * 2001-12-17 2003-06-30 International Barcode Corporation Double-sided bar code doubling as a single bar code
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
IL162203A0 (en) * 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
JP2005528344A (en) * 2002-02-15 2005-09-22 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Method for producing indolinone derivatives
AU2003233576A1 (en) * 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
ITMI20021620A1 (en) * 2002-07-23 2004-01-23 Novuspharma Spa ANTI-TUMORAL ACTIVITY COMPOUND
US20060084697A1 (en) * 2002-08-08 2006-04-20 Hallahan Dennis E Pi3k antagonists as radiosensitizers
WO2004015082A2 (en) * 2002-08-09 2004-02-19 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
AU2003302665B2 (en) * 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
AR042042A1 (en) * 2002-11-15 2005-06-08 Sugen Inc COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
PL216368B1 (en) 2003-02-26 2014-03-31 Sugen Aminoheteroaryl compounds as protein kinase inhibitors
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334582A1 (en) * 2003-07-28 2005-02-24 Basf Ag Maleic anhydride production by VPO-catalyzed gas-phase oxidation of n- butane involves setting the n-butane and oxygen content levels in a pressure- controlled feed to reduce risk of explosions
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
ATE473223T1 (en) * 2003-10-02 2010-07-15 Pharmacia & Upjohn Co Llc SALTS AND POLYMORPHOIC FORMS OF A PYRROLE-SUBSTITUTED INDOLINONE COMPOUND
PT1680140E (en) * 2003-10-16 2011-05-31 Imclone Llc Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP1692085A4 (en) 2003-11-07 2010-10-13 Novartis Vaccines & Diagnostic INHIBITION OF FGFR3 RECEPTOR AND TREATMENT OF MULTIPLE MYELOMA
JP4303726B2 (en) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Urea derivative and method for producing the same
WO2005053614A2 (en) * 2003-11-26 2005-06-16 The Scripps Research Institute Advanced indolinone based protein kinase inhibitors
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
SE0401790D0 (en) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
UA87153C2 (en) * 2004-08-26 2009-06-25 Пфайзер Инк. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
JP4834553B2 (en) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition
CN100432071C (en) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 Substituted 1H-indol-2-one compound and its preparation method and use
GT200500321A (en) 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
BRPI0607579A2 (en) * 2005-03-23 2009-09-15 Pfizer Prod Inc use of anti-ctla4 antibody and indolinone for the preparation of cancer treatment drugs
EP2444419A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
WO2006120557A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CN102898364A (en) 2005-05-18 2013-01-30 阵列生物制药公司 Heterocyclic inhibitors of MEK and methods of use thereof
US20110178097A1 (en) 2005-05-23 2011-07-21 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
AU2006249790A1 (en) * 2005-05-26 2006-11-30 The Scripps Research Institute Enhanced indolinone based protein kinase inhibitors
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
ZA200802971B (en) 2005-09-07 2009-10-28 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
US20080275101A1 (en) * 2005-09-19 2008-11-06 Pfizer Inc. Solid Salt Forms Of A Pyrrole Substituted 2-Indolinone
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
US20090068718A1 (en) * 2005-12-29 2009-03-12 Congxin Liang Amino acid derivatives of indolinone based protein kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
CN101007801A (en) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses
AR060358A1 (en) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic QUINAZOLINS FOR THE INHIBITION OF PDK 1
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
KR20080110912A (en) 2006-04-19 2008-12-19 노파르티스 아게 Inhibition method of indazole compound and CD7
AU2007251282A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
DE102006024834B4 (en) * 2006-05-24 2010-07-01 Schebo Biotech Ag New indole pyrrole derivatives and their uses
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
EP2040738A1 (en) 2006-07-13 2009-04-01 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
AR062207A1 (en) 2006-08-04 2008-10-22 Takeda Pharmaceutical IMIDAZOPIRIDAZINE DERIVATIVES INHIBITORS OF USEFUL KINASES TO PREVENT AND / OR TREAT CANCER.
KR101438245B1 (en) 2006-08-23 2014-09-04 쿠도스 파마슈티칼스 리미티드 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2079727B1 (en) 2006-09-15 2016-02-17 Xcovery, INC. Kinase inhibitor compounds
DK2087001T3 (en) 2006-11-02 2017-02-06 Acceleron Pharma Inc ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND APPLICATIONS THEREOF
JP4623604B2 (en) * 2006-11-06 2011-02-02 株式会社セラバリューズ Novel oxindole derivatives
BRPI0718029A2 (en) 2006-11-06 2013-11-26 Supergen Inc IMIDAZO (1,2-B) PYRIDAZINE AND PIRAZOLE (1,5-A) PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
JP5542445B2 (en) 2006-12-04 2014-07-09 江▲蘇▼先声▲薬▼物研究有限公司 3-pyrrolocyclohexylidene-2-dihydroindolinone derivatives and uses thereof
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CU20090141A7 (en) 2007-02-06 2011-04-26 Pfizer 2-AMINO PYRIMIDINE COMPOUNDS
WO2008114819A1 (en) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008138184A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US20090062368A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
DK2197878T3 (en) * 2007-09-06 2016-11-14 Boston Biomedical Inc FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases
ME01999B (en) 2007-10-11 2015-05-20 Astrazeneca Ab Pyrrolo[2, 3 -d]pyrimidin derivatives as protein kinase b inhibitors
WO2009060945A1 (en) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2699305A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CN101939314B (en) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 Polymorphic forms of a 3-pyrrole substituted 2-indolinone
PT2222675E (en) 2007-12-19 2013-11-13 Genentech Inc 5-anilinoimidazopyridines and methods of use
EA201000947A1 (en) 2007-12-20 2011-02-28 Новартис Аг DERIVATIVES OF THIAZOLES APPLICABLE AS KINASE PI3 INHIBITORS
US8486963B2 (en) 2007-12-21 2013-07-16 Genentech, Inc. Azaindolizines and methods of use
MX2010008187A (en) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Combined use of angiogenesis inhibitor and taxane.
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CN101255154B (en) * 2008-02-18 2011-09-07 靳广毅 Substituted 2-indoline ketone derivatives as well as preparation method and uses thereof
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
KR20100119582A (en) * 2008-03-31 2010-11-09 테바 파마슈티컬 인더스트리즈 리미티드 Processes for preparing sunitinib and salts thereof
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
KR101375156B1 (en) * 2008-05-23 2014-03-18 쟝수 치아타이 티안큉 파마수티컬 주식회사 Dihydroindolinone derivatives
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
EP2313371B1 (en) * 2008-06-13 2012-08-15 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
KR20110036055A (en) 2008-06-23 2011-04-06 낫코 파마 리미티드 Improved process for the preparation of high purity sunitinib and its pharmaceutically acceptable salts
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CN102137866A (en) * 2008-06-30 2011-07-27 赛林药物股份有限公司 Oxindole compounds
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
DE102008031038A1 (en) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Use of 2-indolinone derivatives for the treatment of organ transplantation
CN102137842A (en) * 2008-07-02 2011-07-27 基因里克斯(英国)有限公司 Preparation of 3-pyrrole substituted 2-indolinone derivatives
US20110257237A1 (en) * 2008-07-10 2011-10-20 Generics [Uk] Limited Process for the preparation of crystalline forms of sunitinib malate
EP2373642A2 (en) * 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
EA023148B1 (en) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Compositions of pd-1 antagonists and use thereof
JP2012500838A (en) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド A novel polymorph of sunitinib and process for its preparation
US20120029046A1 (en) * 2008-08-25 2012-02-02 Generics (Uk) Limited Crystalline form of sunitinib and processes for its preparation
CA2735006A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
AU2009289062B2 (en) * 2008-09-05 2015-01-22 Hammersmith Imanet Limited Isatin derivatives for use as in vivo imaging agents
CN102264763B (en) 2008-09-19 2016-04-27 米迪缪尼有限公司 Antibody being oriented to DLL4 and uses thereof
CN102177155A (en) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
JP5579619B2 (en) 2008-12-01 2014-08-27 武田薬品工業株式会社 Heterocyclic compounds and uses thereof
JO3101B1 (en) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
UY32351A (en) 2008-12-22 2010-07-30 Astrazeneca Ab PIRIMIDINIL INDOL COMPOUNDS FOR USE AS ATR INHIBITORS
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
EP2373643A4 (en) 2009-01-02 2013-08-07 Hetero Research Foundation Novel polymorphs of sunitinib malate
TW201920110A (en) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 Containing N-(4-{[6,7-bis(methoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-di Pharmaceutical composition of methotrexate malate and use thereof
ES2604668T3 (en) 2009-02-05 2017-03-08 Immunogen, Inc. New benzodiazepine derivatives
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
ES2529205T3 (en) 2009-03-13 2015-02-17 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2419423A1 (en) 2009-04-14 2012-02-22 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2264027A1 (en) * 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
CN101906076B (en) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
FR2948940B1 (en) * 2009-08-04 2011-07-22 Servier Lab NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP2475648A1 (en) 2009-09-11 2012-07-18 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
CN102666545B (en) 2009-10-20 2016-04-06 塞尔卓姆有限公司 As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
RU2706200C2 (en) 2009-11-24 2019-11-14 Медиммьюн Лимитед Specific binding agents against b7-h1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011095802A1 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing sunitinib
WO2011100325A2 (en) * 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
BR112012019635A2 (en) 2010-02-22 2016-05-03 Hoffmann La Roche pyrido [3,2-d] pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011104555A2 (en) * 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
EP2542550A1 (en) 2010-03-04 2013-01-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011119777A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011128699A2 (en) * 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
MX2012012328A (en) 2010-04-30 2013-05-06 Cellzome Ltd Pyrazole compounds as jak inhibitors.
WO2011138565A1 (en) 2010-05-05 2011-11-10 Biorebus Pharmaceutical combination containing lipoic acid, hydroxycitric acid and a somatostatin as active ingredients
EP2392324A1 (en) 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl compounds for use as ATR inhibitors
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
AR082418A1 (en) 2010-08-02 2012-12-05 Novartis Ag CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012058780A1 (en) 2010-11-01 2012-05-10 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
WO2012059941A1 (en) * 2010-11-04 2012-05-10 Ind-Swift Laboratories Limited Process for preparation of sunitinib malate and salts thereof
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
JP2014503500A (en) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション Preselection of subjects suitable for treatment with oxygen-sensitive drugs based on hypoxia
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
TWI410425B (en) 2010-12-03 2013-10-01 Lilly Co Eli Oxazolo[5,4-b]pyridin-5-yl compounds
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
CA2825605C (en) 2011-01-31 2019-05-07 Novartis Ag Heterocyclic derivatives
SG191965A1 (en) 2011-02-15 2013-08-30 Immunogen Inc Methods of preparation of conjugates
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN102115469A (en) * 2011-03-21 2011-07-06 浙江大学 Preparation method for indoline-2-one derivative and application of same
JP2014510122A (en) 2011-04-04 2014-04-24 セルゾーム リミテッド Dihydropyrrolopyrimidine derivatives as mTOR inhibitors
SG193527A1 (en) * 2011-04-08 2013-10-30 Beta Pharma Inc New indolinone protein kinase inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
BR112013021941B1 (en) 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd THERAPEUTIC AGENT FOR TUMOR
CN102898402B (en) * 2011-04-26 2016-01-20 北京大学 The indole ketone compound that the minaline ester that a kind of Benzisoelenazolone is modified replaces and application thereof
ES2841809T3 (en) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarkers to predict and evaluate the degree of response of subjects with thyroid and kidney cancer to lenvatinib compounds
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
JP2014521623A (en) 2011-07-28 2014-08-28 セルゾーム リミティッド Heterocyclyl pyrimidine analogs as JAK inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
RU2014115476A (en) 2011-09-20 2015-10-27 Целльзом Лимитед PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS
EP2758379B1 (en) 2011-09-21 2016-10-19 Cellzome Limited Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
CN102499917B (en) 2011-10-25 2014-12-17 澳门大学 Application of indolone compounds in preparing nerve protection medicine
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN103130774B (en) * 2011-11-22 2016-06-22 齐鲁制药有限公司 Compound with tyrosine kinase inhibitory activity and its preparation method and application
CN103127096B (en) * 2011-12-02 2015-11-25 杨子娇 The Benzazole compounds that pyrrole radicals replaces is in the application for the treatment of glaucoma
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CA2860095A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN102491932A (en) * 2011-12-26 2012-06-13 天津科技大学 3-indoline ketone derivative, and preparation method and application thereof
ES2709110T3 (en) 2012-03-23 2019-04-15 Laurus Labs Ltd An improved process for the preparation of sunitinib and its acid addition salts
IN2014MN02105A (en) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
PL399027A1 (en) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Preparation method for high purity N- [2- (diethylamino) ethyl] -5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide and its use in the production of sunitinib
CN102653521B (en) * 2012-04-27 2014-08-06 首都师范大学 Piperazine thiocarbohydrazide derivate of indole-2-ketone and preparation method and application of piperazine thiocarbohydrazide derivate
SI2844282T1 (en) 2012-05-04 2019-08-30 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CN104583235B (en) 2012-06-08 2019-03-01 苏特罗生物制药公司 The antibody of the Unnatural amino acid residues containing site-specific, its preparation and application
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SI2890402T1 (en) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
ES2644758T3 (en) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. PKM2 modulators and methods for use
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd Amorphous form of quinoline derivative, and method for producing same
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219422A1 (en) 2013-02-28 2017-04-07 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2970206A1 (en) * 2013-03-13 2016-01-20 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014236820B2 (en) 2013-03-14 2018-08-02 Sumitomo Pharma Oncology, Inc. JAK2 and ALK2 inhibitors and methods for their use
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119321B (en) * 2013-04-28 2017-09-08 齐鲁制药有限公司 The 2-maleate and its polymorph of indolinone derivative
MX368099B (en) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
FR3008411B1 (en) * 2013-07-12 2015-07-03 Servier Lab NOVEL 3 - [(3 - {[4- (4-MORPHOLINYLMETHYL) -1H-PYRROL-2-YL] METHYLENE} -2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL) METHYL SALT ] -1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND THE FORMULATIONS CONTAINING IT
JP6612232B2 (en) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） Gene expression signatures for predicting responsiveness to multikinase inhibitors of interest, and uses thereof
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
SG11201602625YA (en) 2013-11-01 2016-05-30 Pfizer Vectors for expression of prostate-associated antigens
TN2016000179A1 (en) 2013-12-06 2017-10-06 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
CN104829596B (en) 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 Pyrrole-substituted indolinone derivative and preparation method thereof, composition including derivative, and application of derivative
CN103923014A (en) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 Preparation method of cyclocreatine
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
SI3524595T1 (en) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
DK3298021T3 (en) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc ALVOCIDIB PRODRUGS THAT HAVE INCREASED BIOTAILABILITY
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
MX373231B (en) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd ANTICANCER AGENT.
MX2018001289A (en) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Combination therapies for treatment of cancer.
KR102587702B1 (en) 2015-08-20 2023-10-12 에자이 알앤드디 매니지먼트 가부시키가이샤 tumor treatment
KR20180058758A (en) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. Compounds and compositions for the treatment of ocular disorders
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
HK1257499A1 (en) 2015-11-12 2019-10-25 Graybug Vision, Inc. Aggregating microparticles for therapy
MX2018009085A (en) 2016-01-27 2019-05-09 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates.
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
CN107459519A (en) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 Annelated pyrimidines piperidines ring derivatives and its preparation method and application
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
SG11201903483VA (en) 2016-10-28 2019-05-30 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3045517A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP6581320B2 (en) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition for tumor treatment
CN106916143B (en) * 2017-03-14 2019-09-27 哈尔滨医科大学 A kind of medicine for preventing and treating coronary heart disease and its application
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. MEDICINAL PRODUCTS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
MX2019013363A (en) 2017-05-10 2020-01-13 Graybug Vision Inc Extended release microparticles and suspensions thereof for medical therapy.
MX2019013014A (en) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma.
EP3658588A1 (en) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
JP7423513B2 (en) 2017-09-18 2024-01-29 ストロ バイオファーマ インコーポレーテッド Anti-folate receptor α antibody conjugate and its use
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EP3802519A1 (en) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai LINKS TO DEGRADING / DESTRUCTING WD40-REPEAT-DOMAIN-RPOTEIN 5 (WDR5) AND THEIR USE
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN113195000A (en) 2018-12-21 2021-07-30 第一三共株式会社 Combination of antibody-drug conjugates and kinase inhibitors
JP7662528B2 (en) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド Formulations Containing Heterocyclic Protein Kinase Inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
CN118908962A (en) * 2019-05-06 2024-11-08 西奈山伊坎医学院 Heterobifunctional compounds as degradation agents for HPK1
CN114728910B (en) 2019-08-31 2024-05-14 上海奕拓医药科技有限责任公司 Pyrazole derivative for FGFR inhibitor and preparation method thereof
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN111233841A (en) * 2020-03-17 2020-06-05 湖北扬信医药科技有限公司 A kind of sunitinib related substance and preparation method and use thereof
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP7633786B2 (en) 2020-09-18 2025-02-20 日本化薬株式会社 Pharmaceutical tablets containing sunitinib malate as the active ingredient
US20240293365A1 (en) * 2021-06-28 2024-09-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
CN113717159A (en) * 2021-09-16 2021-11-30 中国药科大学 Indolone compounds and pharmaceutical composition, preparation method and application thereof
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
AU2023300170A1 (en) 2022-06-30 2025-01-09 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024017372A1 (en) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 Indolone derivative and use thereof
CN118221652B (en) * 2022-12-19 2025-06-06 沈阳药科大学 Indole-2-one derivative and preparation method and use thereof
WO2024188282A1 (en) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 Indolone derivative and use thereof in medicine
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104796C (en) 1957-08-19
DE878539C (en) 1939-08-17 1953-06-05 Hoechst Ag Process for the production of methine dyes
BE507136A (en) 1950-11-18
BE553661A (en) 1955-12-23
BE558210A (en) 1956-06-08
NL251055A (en) 1959-04-29
FR1398224A (en) 1964-05-06 1965-05-07 Ici Ltd Process for dyeing polyacrylonitrile textile materials
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3551571A (en) 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
US3564016A (en) 1968-03-07 1971-02-16 Endo Lab Method of decarbonylation
US4070366A (en) 1968-06-12 1978-01-24 Canadian Patents & Development Limited Alkylation process
FR1599772A (en) 1968-09-17 1970-07-20
US3922163A (en) 1970-01-30 1975-11-25 Upjohn Co Organic compounds and process
US3715364A (en) 1970-12-28 1973-02-06 Merck & Co Inc Nitroimidazole carboxamides
DE2159363A1 (en) 1971-11-30 1973-06-14 Bayer Ag Antimicrobial nitrofurans - useful eg as feed additives
DE2159362A1 (en) 1971-11-30 1973-06-14 Bayer Ag Amino-3-(5-nitro-2-furfurylidene)oxindoles - with antibacterial and antimycotic activity
DE2159360A1 (en) 1971-11-30 1973-06-14 Bayer Ag Acylamino-3-(5-nitro-2-furfurylidene) oxindoles - with antibacterial and antimycotic activity
DE2159361A1 (en) 1971-11-30 1973-06-14 Bayer Ag Diacylamino-3-(5-nitro-2-furfurylidene) oxindoles - - with antibacterial and antimycotic activity
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US3880871A (en) 1973-09-27 1975-04-29 Squibb & Sons Inc Isothiocyanophenyl substituted imidazoles
US4002643A (en) 1975-06-27 1977-01-11 Mcneil Laboratories, Inc. Preparation of β-acyl pyrroles
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2855306A1 (en) 1978-12-21 1980-07-10 Boehringer Sohn Ingelheim HEART RATE REDUCTION AGENT
GR73560B (en) 1979-02-24 1984-03-15 Pfizer
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4343923A (en) 1980-08-07 1982-08-10 Armstrong World Industries, Inc. Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound
CH646956A5 (en) 1981-12-15 1984-12-28 Ciba Geigy Ag Imidazolides.
EP0095285A1 (en) 1982-05-21 1983-11-30 Sumitomo Chemical Company, Limited N-acylimidazoles, their production and use
US4493642A (en) 1982-12-27 1985-01-15 Bogdon Glendon J Orthodontic device and associated orthodontic method
DE3310891A1 (en) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim NEW INDOLINON (2) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS
US4489089A (en) 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
EP0124482B1 (en) 1983-04-29 1989-11-08 Ciba-Geigy Ag Imidazolides and their use as curing agents for polyepoxides
DE3415138A1 (en) 1984-04-21 1985-10-31 Basf Ag, 6700 Ludwigshafen N- (AZOLYLCARBAMOYL) HYDROXYLAMINE AND FUNGICIDES CONTAINING THEM
DE3426419A1 (en) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim NEW OXINDOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, AND INTERMEDIATE PRODUCTS
US4560700A (en) 1985-02-08 1985-12-24 Merrell Dow Pharmaceuticals Inc. Pyrrole-3-carboxylate cardiotonic agents
JPH078851B2 (en) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 3-phenylthiomethylstyrene derivative
JPS6229570A (en) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound
JPS6239564A (en) 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd Alpha-benzylidene-gamma-butyrolactone or gamma-butyrolactam derivative
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4853404A (en) 1986-10-13 1989-08-01 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives composition and use
JPS63141955A (en) 1986-12-03 1988-06-14 Kanegafuchi Chem Ind Co Ltd Tribenzylamine derivative
EP0304493B1 (en) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5043348A (en) 1987-04-24 1991-08-27 Cassella Aktiengesellschaft Pyrrolealdehydes, their preparation and their use
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3808071A1 (en) 1988-03-11 1989-09-21 Basf Ag METHOD FOR PRODUCING ACYLATED IMIDAZOLES
US4868304A (en) 1988-05-27 1989-09-19 Iowa State University Research Foundation, Inc. Synthesis of nitrogen heterocycles
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
JPH06104658B2 (en) 1988-06-23 1994-12-21 三菱化成株式会社 Pyrrolecarboxylic acid derivative
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
DE3824658A1 (en) 1988-07-15 1990-01-18 Schering Ag N-HETARYL IMIDAZOLE DERIVATIVES
US5084280A (en) 1988-12-15 1992-01-28 Chapman Chemical Company Wood preservation composition and method
DE3902439A1 (en) 1989-01-27 1990-08-02 Basf Ag PLANT PROTECTIVE AGENTS BASED ON 1-ARYL OR 1-HETARYLIMIDAZOLE CARBONIC ACID ESTERS
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
EP0429685B1 (en) 1989-07-25 1997-10-29 Taiho Pharmaceutical Company, Limited Oxoindole derivative
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
CA2032421A1 (en) 1989-12-20 1991-06-21 Mitsubishi Chemical Corporation Pyrrolealdehyde derivative
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
DE69105495T2 (en) 1990-04-02 1995-04-06 Pfizer BENZYLPHOSPHONIC ACID TYROSINKINAS INHIBITORS.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JP2944721B2 (en) 1990-08-22 1999-09-06 生化学工業株式会社 Endotoxin measuring agent
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
IT1247509B (en) 1991-04-19 1994-12-17 Univ Cagliari SYNTHESIS COMPOUNDS FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS
ES2108120T3 (en) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (en) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd Antitumor agent
HU219131B (en) 1991-10-18 2001-02-28 Monsanto Co. Method and fungicidal composition for the control of take-all disease of plants and the active ingredients
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2689397A1 (en) 1992-04-01 1993-10-08 Adir Use of di:tert-butyl-4-hydroxy-benzylidenyl-indoline-2-one - as an antioxidant, prostanoid synthesis inhibitor and platelet anti aggregant to treat atheroma, arteriosclerosis inflammatory diseases, etc.
DE4211531A1 (en) 1992-04-06 1993-10-07 Cassella Ag Process for the preparation of pyrrole derivatives
WO1993023040A1 (en) 1992-05-20 1993-11-25 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
FR2694004B1 (en) 1992-07-21 1994-08-26 Adir News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them.
RU2155187C2 (en) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Derivatives of indole, their tautomers, mixtures of their isomers or separate isomers and pharmaceutically acceptable salts, pharmaceutical composition showing antitumor or inhibiting protein tyrosine kinase activity and method of inhibition of protein tyrosine kinase-depending disease or control of aberrant growth of mammalian or human cells
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
DE69233803D1 (en) 1992-10-28 2011-03-31 Genentech Inc Use of vascular endothelial growth factor antagonists
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JP3507124B2 (en) 1993-05-26 2004-03-15 塩野義製薬株式会社 Method for producing benzylidene derivative
DE59402281D1 (en) 1993-06-28 1997-05-07 Bayer Ag Bulk dyeing of plastics
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5332736A (en) 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3246712B2 (en) 1995-11-15 2002-01-15 株式会社トクヤマ Method for producing ethenylamide compound
EP0815859B1 (en) 1996-01-17 2003-06-18 Taiho Pharmaceutical Company Limited Intimal thickening inhibitors
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
WO1997034920A1 (en) 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
AU706839B2 (en) 1996-03-29 1999-06-24 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ANT)agonists of 5-HT1A- and/or 5-HT1D receptors
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
JP2000515529A (en) 1996-08-01 2000-11-21 メルクル・ゲーエムベーハー Acylpyrrolidone dicarboxylic acid, acyl indole dicarboxylic acid and derivatives thereof as inhibitors of cytoplasmic phospholipase A
AU733890B2 (en) 1996-08-21 2001-05-31 Sugen, Inc. Crystal structures of a protein tyrosine kinase
AU4155697A (en) 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
AU7622698A (en) 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
CO4940469A1 (en) 1997-03-05 2000-07-24 Sugen Inc ORAL COMPOSITION OF IMPROVED STABILITY INCLUDING A DERIVATIVE OF INDOLINONE AND A MIXTURE OF GLYCERIDES OR POLYETHYLENE GLYCOL ESTERS
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA58476C2 (en) 1997-10-09 2003-08-15 Санофі-Сентелябо 8-AZABICYCLO[3.2.1]OCTANE-3-METHANAMINE DERIVATIVES, ITS PREPARATION AND APPLICATION IN therapeutics
WO1999048868A2 (en) 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
DE19816624A1 (en) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
JP4528440B2 (en) * 1998-05-29 2010-08-18 スージェン， インク． Pyrrole substituted 2-indolinone protein kinase inhibitor
DE19826940A1 (en) 1998-06-17 1999-12-23 Bayer Ag Substituted N-aryl-O-alkyl-carbamates
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
CN1526448A (en) 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ Medicine and method for the treatment of anorectal disorders
DK1157019T3 (en) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, especially CDK2
US6284894B1 (en) 1998-12-18 2001-09-04 Nycomed Imaging As Preparation of allylic aromatic compounds
AU760964B2 (en) * 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
AU3770000A (en) 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DE60029138T2 (en) * 1999-12-22 2007-06-06 Sugen, Inc., San Francisco Use of indolinone compounds for the production of pharmaceuticals for the modulation of the function c-kit protein tyrosine kinase
DE122008000002I1 (en) * 2000-02-15 2008-04-17 Sugen Inc PYRROL SUBSTITUTED INDOLIN-2-ON PROTEIN KINASE INHIBITORS
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AU2001270260A1 (en) * 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6677368B2 (en) * 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones

Also Published As

Publication number Publication date
AU3977001A (en) 2001-08-27
NO325532B1 (en) 2008-06-09
IS6501A (en) 2002-08-13
TWI306860B (en) 2009-03-01
BRPI0108394B8 (en) 2021-05-25
IS2491B (en) 2009-01-15
US20020156292A1 (en) 2002-10-24
NO2008019I1 (en) 2009-01-12
US7125905B2 (en) 2006-10-24
DE60129794T2 (en) 2007-12-06
NL300430I2 (en) 2010-04-01
LTC1255752I2 (en) 2019-08-26
BRPI0117360A2 (en) 2012-01-24
EA200200862A1 (en) 2003-02-27
MXPA02008021A (en) 2004-04-05
SK13262002A3 (en) 2003-03-04
US7572924B2 (en) 2009-08-11
WO2001060814A3 (en) 2002-01-24
SK287142B6 (en) 2010-01-07
JP2003523340A (en) 2003-08-05
EA005996B1 (en) 2005-08-25
UA73976C2 (en) 2005-10-17
BG107078A (en) 2003-04-30
CA2399358C (en) 2006-03-21
CY2008004I2 (en) 2009-11-04
US20050176802A1 (en) 2005-08-11
SI1255752T1 (en) 2007-12-31
CY2008004I1 (en) 2009-11-04
LTPA2008002I1 (en) 2019-02-25
WO2001060814A2 (en) 2001-08-23
NO2008019I2 (en) 2011-10-17
DE122010000004I1 (en) 2010-04-15
NO2019005I1 (en) 2019-02-11
FR08C0002I2 (en) 2009-01-02
JP3663382B2 (en) 2005-06-22
LU91657I2 (en) 2010-05-03
AR034118A1 (en) 2004-02-04
DE60129794D1 (en) 2007-09-20
KR20030003229A (en) 2003-01-09
HUP0204433A3 (en) 2007-08-28
DK1255752T3 (en) 2007-11-26
KR100713960B1 (en) 2007-05-02
CZ303705B6 (en) 2013-03-27
CR20120007A (en) 2012-02-24
ME00415B (en) 2011-10-10
EP1255752A2 (en) 2002-11-13
BRPI0108394B1 (en) 2018-12-11
CR20120009A (en) 2012-02-07
AU2001239770B2 (en) 2006-01-05
NO2010002I1 (en) 2010-03-08
LU91407I9 (en) 2018-12-28
BRPI0117360B1 (en) 2018-11-13
NL300332I2 (en) 2008-04-01
DE122008000002I1 (en) 2008-04-17
CN1439005A (en) 2003-08-27
ATE369359T1 (en) 2007-08-15
HU228979B1 (en) 2013-07-29
CO5280092A1 (en) 2003-05-30
EP1255752B1 (en) 2007-08-08
CA2399358A1 (en) 2001-08-23
FR10C0003I1 (en) 2010-03-05
NZ520640A (en) 2005-04-29
CY1108032T1 (en) 2011-04-06
LU91407I2 (en) 2008-03-10
HRP20020751B1 (en) 2011-01-31
PL361209A1 (en) 2004-09-20
RS50444B (en) 2010-03-02
YU61402A (en) 2005-07-19
US20070010569A1 (en) 2007-01-11
NL300430I1 (en) 2010-03-01
US6573293B2 (en) 2003-06-03
MY130363A (en) 2007-06-29
NO2010002I2 (en) 2010-12-06
CY2010004I1 (en) 2012-01-25
HUP0204433A2 (en) 2003-04-28
NL300332I1 (en) 2008-03-03
NO20023831D0 (en) 2002-08-13
ES2290117T3 (en) 2008-02-16
FR08C0002I1 (en) 2008-03-21
BG65764B1 (en) 2009-10-30
BR0108394A (en) 2004-06-22
BE2010C009I2 (en) 2020-01-30
HK1051188A1 (en) 2003-07-25
PT1255752E (en) 2007-10-17
NO20023831L (en) 2002-10-15
CZ20023081A3 (en) 2003-02-12
CY2010004I2 (en) 2012-01-25
BRPI0117360B8 (en) 2021-07-06
PE20011083A1 (en) 2001-10-26
US20040063773A1 (en) 2004-04-01
PL211834B1 (en) 2012-06-29
HRP20020751A2 (en) 2004-12-31
IL151127A0 (en) 2003-04-10
CN1329390C (en) 2007-08-01

Similar Documents

Publication Publication Date Title
FR08C0002I2 (en) PYRROLE-SUBSTITUTED PROTEIN KINASE 2-INDOLINONE INHIBITORS
NO20005916D0 (en) Pyrrole-substituted 2-indolinone protein kinase inhibitors
ID30460A (en) INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN
ATE445613T1 (en) INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS
PT1317448E (en) UIRAL PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS
PT1345922E (en) UIRAL PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS
EE200300175A (en) Cyanopyrrolidine derivatives
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
NL300242I1 (en) Mega-carboxyaryl substituted diphenylureas as well as kinase inhibitors.
NO20021820L (en) Tyrosine kinase inhibitors
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
ATE330940T1 (en) PYRROLIDINE DERIVATIVES USABLE AS BAX INHIBITORS
NO20025659L (en) Heterocyclic compounds
DK1178990T3 (en) Imidazodiazepine derivatives.
PT1246799E (en) REPLACED PYRROL MANNICH BASES
DE60133444D1 (en) Double-walled fuel distributor
NO20002870L (en) MYT1 kinase inhibitors
DK1256576T3 (en) Condensed imidazolium derivatives
UA5237S (en) THERMOSTAT CABINET FOR GAS CYLINDERS
DK1305307T3 (en) indole derivatives
UA4560S (en) COVER FOR BOOKS
HK1054925A (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
ES1046326Y (en) ALGARROBAS PICKUP